Apidra Use In Pregnancy & Lactation

Pregnancy: There are no adequate data on the use of insulin glulisine in pregnant women.
A limited amount of data on pregnant women (less than 300 pregnancy outcomes reported) exposed to marketed insulin glulisine indicates no safety issues in use of insulin glulisine during pregnancy or on the foetus and newborn child.
Caution should be exercised when prescribing to pregnant women. Careful monitoring of glucose control is essential. It is essential for patients with pre-existing or gestational diabetes to maintain good metabolic control throughout pregnancy. Insulin requirements may decrease during the first trimester and generally increase during the second and third trimesters. Immediately after delivery, insulin requirements decline rapidly. Patients with diabetes must inform their doctor if they are pregnant or are contemplating pregnancy.
Lactation: It is unknown whether insulin glulisine is excreted in human milk, but in general insulin does not pass into breast milk and is not absorbed after oral administration.
Breast-feeding mothers may require adjustments in insulin dose and diet.